FA
COLL icon

Friess Associates’s Collegium Pharmaceutical COLL Stock Holding History

Friess Associates’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-133,594
Closed -$2.78M – 102
2020
Q3 		$2.78M Buy
133,594
+7,668
+6% +$138K 0.24% 71
2020
Q2 		$2.2M Buy
+125,926
New +$2.47M 0.21% 78

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Friess Associates's COLL Position: Q4 2020 in Review

Friess Associates sold out of Collegium Pharmaceutical (COLL) in Q4 2020, closing a stake of 133,594 shares — an estimated $2.78M sold.

Friess Associates first reported a position in COLL in Q2 2020 and held it in 2 quarters. The position peaked at $2.78M in Q3 2020. 138 funds tracked by Wall St. Rank hold COLL as of Q4 2020.

  • Friess Associates reported no remaining Collegium Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Friess Associates sold 133,594 Collegium Pharmaceutical shares in Q4 2020, an estimated $2.78M.
  • Friess Associates first reported a position in Collegium Pharmaceutical in Q2 2020 and held it in 2 quarters.
  • Friess Associates's Collegium Pharmaceutical position peaked at $2.78M in Q3 2020.
  • 138 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2020.

Based on Friess Associates's 13F filing for Q4 2020, filed 12 Feb 2021.